- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Rebyota was recently approved as the first live microbiome-based therapeutic for the prevention of recurrent Clostridioides difficile infection (CDI) and works by restoring the functionality of a patient’s microbiome after antibiotic treatment, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Can you explain the mechanism of action for Rebyota and the significance of its FDA approval as the first fecal transplant therapy for the prevention of recurrent CDI?
So, it's certainly very exciting that Rebyota was just approved. This is going to be the first live microbiome-based therapeutic that we have—we generally call these products LPBs [live biotherapeutic products]. This is a rectally administered therapy that's meant to be done in the office or in the hospital setting. And again, it's indicated for the prevention of recurrent CDI.
What we know is that with CDI, the patient took antibiotics, which likely led to this infection, and then multiple rounds of antibiotics to treat. And so you've essentially ablated your gut microbiome. Therapies such as Rebyota are really meant to replace the ecology of your gut microbiome, and restore functionality of your microbiome so that you can be able to overcome this infection.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
